But this was not supported by other studies, although in one study n-3 PUFA supplementation (4 g/d, 12 months) resulted in a reduction in serum pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 while increasing anti-inflammatory IL-10 levels in treated MS patients [201]. The gene discussed is IL1B; the disease is myeloid sarcoma.